INNOVATION THAT MATTERS

Solid as a Rock: Creating a Strong Foundation for Developing First-in-Class Treatments to Fight...

By Rich Soll, Senior Vice President, Research Service Division, WuXi AppTec (@richsollwx) In the life sciences, disruptive innovation is no longer the exception; it’s the rule. One global R&D executive known for...

Brave Science: Putting the ‘Hutzpah’ in Early-Stage Drug Discovery

By Rich Soll, SVP of Research Service Division at WuXi AppTec (@richsollwx) From developing new paradigms for early-stage drug discovery for rare and common diseases to fostering the convergence of peptide nanotechnology, and launching...

INDUSTRY BEATS

WUXI NEWS

WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

We are excited to announce that WuXi has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). After completion of acquisition, HD Biosciences will become...

FDA DRUG APPOVALS / DESIGNATIONS

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Artificial Intelligence Poised to Transform the Drug Industry from Laboratory to...

Artificial intelligence (AI) –  which learns from computer algorithms how to unravel complex genomic data, such as gene expression patterns of disease – is...